-+ 0.00%
-+ 0.00%
-+ 0.00%

Oric Pharmaceuticals Reports Promising Phase 1b Results for Enozertinib in NSCLC with EGFR Exon 20 Mutations

Reuters·12/06/2025 01:00:18

Please log in to view news